Abstract Nephrotoxicity is one of critical problems of aminoglycoside antibiotics. We examined the protective effect of apolipoprotein E3 (apoE3), one of ligands for megalin, on neomycin-induced extracellular release of lactate dehydrogenase, a marker of cell necrosis using pig proximal tubular LLC-PK 1 cells. Neomycin significantly induced the extracellular release of lactate dehydrogenase, but apoE3 successfully suppressed it. This result indicated that apoE3 protects the proximal tubular cells from the eventual cell death induced by nephrotoxic aminoglycosides.
lipoprotein (LDL) receptor. Our previous study demonstrated that an apolipoprotein E3 (apoE3), one of ligands for megalin, significantly protects pig proximal tubular LLC-PK1 cells from gentamicin C (GMC)-induced reduction in SGLT1 (Na ϩ /glucose cotransporter) activity and from GMC-induced extracellular release of N-acethylb -D-glucosamidase (NAG), a marker of lysosomal destabilization [3] . Neomycin is one of the most severe nephrotoxic aminoglycosides [4] and strongly inhibits the dome formation in LLC-PK 1 cells [5] . The extracellular release of lactate dehydrogenase (LDH) is a marker of cell death and rupture of the cell membrane and significantly induced by severe nephrotoxic aminoglycosides such as neomycin and gentamicin [6, 7] . In this study, using the model of extracellular release of LDH from LLC-PK 1 cells, we studied whether ligands for megalin protect the cells from neomycin-induced LDH release.
LLC-PK 1 cells were obtained from ATCC (Manassas, VA) and maintained in a Dulbecco's modified Eagle's medium (DMEM; Nissui Pharmaceutical, Japan) supplemented with 10% fetal bovine serum (FBS) at 37°C in a 5% CO 2 environment without addition of antibiotics. We employed apoE3 (CALBIOCHEM) and lactoferrin (Sigma) as ligands for megalin. The cells were inoculated into a 96-well plate at 2ϫ10 5 cells/ml (100 m l/well) with various concentrations of neomycin with or without 4.3 mg/ml of apoE3, 10 mg/ml of lactoferrin or 10 mg/ml of bovine serum albumin (Sigma), and incubated in DMEM supplemented with 5% FBS at 37°C for 4 days. Thereafter, the supernatants of the cultured medium were retrieved and the extracellular release of LDH levels were measured immediately using a Cyto Tox 96 Non-Radioactive Cytotoxicity Assay (Promega) according to the manufacture's instructions.
To establish an appropriate model of neomycin-induced LDH release, the cells were cultured with the addition of 0ϳ200 m g/ml of neomycin and the supernatants were immediately used for the measurement of the extracellular LDH levels. As shown in Fig. 1 , neomycin induced the extracellular release of LDH, with the peak release of LDH at the concentration of 50 mg/ml neomycin. Therefore, we used 50 mg/ml of neomycin for further experiments.
To confirm the protective effect of apoE3 or lactoferrin, considered to be ligands for megalin, the cells were inoculated with 4.3 mg/ml of apoE3, 10 mg/ml of lactoferrin and albumin with or without 50 m g/ml of neomycin. As shown in Fig. 2 , the addition of 4.3 m g/ml of apoE3 significantly reduced the extracellular LDH level induced with 50 mg/ml of neomycin. In contrast to apoE3, neither lactoferrin nor albumin showed any improvement. These proteins stimulated extracellular LDH release in the presence of neomycin. Kounnas et al. reported that the lactoferrin presumably binds away from the binding site of apoE3 [8] . Though albumin constitutes the major plasma protein, megalin indirectly mediates endocytosis of albumin [9] . Therefore, it is suggested that the binding of lactoferrin or albumin to megalin does not affect the binding of aminoglycosides to the site of the receptor.
Taken together, this result indicates that apoE3 protects the cells not only from lysosomal destabilization as determined by NAG [3] , but also from eventual cell death and rupture of the cell membrane as determined by LDH leakage in proximal tubular cells. In summary, apoE3 might have a protective effect against neomycin-induced LDH release in vitro via interference with a binding of aminoglycosides to the site of receptor. 
